主业不振！朗姿股份当“股神”

Core Viewpoint - The major shareholder, Langzi Co., Ltd., has completed its share reduction plan for Ruoyuchen Technology Co., Ltd., reducing its stake to approximately 4.36% and officially exiting the list of significant shareholders holding over 5% [1] Group 1: Shareholding Changes - Langzi Co., Ltd. reduced its holdings in Ruoyuchen from over 5% to 4.36%, retaining 13.55 million shares [1] - Langzi Co., Ltd. initially acquired a 20% stake in Ruoyuchen in 2015 for 110 million yuan [2] - Since September 2022, Langzi Co., Ltd. has been continuously reducing its holdings, cashing out nearly 500 million yuan by September 2025 [2] Group 2: Financial Performance - In the first half of 2025, Langzi Co., Ltd. reported a net profit of 274 million yuan, a year-on-year increase of 64.09%, but the profit excluding gains from share reductions was only 136 million yuan, a decrease of 2.70% [2] - Revenue from Langzi Co., Ltd.'s medical beauty business in the first half of 2025 was 1.333 billion yuan, down 6.1% year-on-year, with significant reliance on its Milan Baiyu brand [2] Group 3: Business Operations and Challenges - Langzi Co., Ltd. is actively pursuing acquisitions in the medical beauty sector, recently announcing a cash acquisition of 67.5% of Chongqing Milan Baiyu Shiguang Medical Beauty Hospital for 92.475 million yuan [3] - The company faces significant financial pressure, with short-term loans increasing from 684 million yuan at the beginning of 2024 to 1.314 billion yuan by year-end [4] - Langzi Co., Ltd. is required to pay back taxes and penalties totaling approximately 30.82 million yuan, which is expected to reduce the company's net profit for 2025 by about 3.082 million yuan, representing 15% of the projected net profit for 2024 [4]